Bridgeway Capital Management, LLC Atreca, Inc. Transaction History

Bridgeway Capital Management, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$0.13 - $0.38 $9,750 - $28,500	-75,000 Reduced 50.0%	75,000 $9,000
Q2 2023 Aug 14, 2023	BUY	$0.88 - $1.22 $44,000 - $61,000	50,000 Added 50.0%	150,000 $147,000
Q1 2022 May 16, 2022	SELL	$1.61 - $5.2 $48,300 - $156,000	-30,000 Reduced 23.08%	100,000 $317,000
Q4 2021 Feb 14, 2022	SELL	$2.87 - $6.29 $60,844 - $133,348	-21,200 Reduced 14.02%	130,000 $394,000
Q3 2021 Nov 15, 2021	BUY	$4.91 - $9.07 $742,392 - $1.37 Million	151,200 New	151,200 $942,000

30.6K

Ticker BCEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,876,000
Description
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-10...

Get notified when there are updates to the investment portfolio of Bridgeway Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Bridgeway Capital Management, LLC with notifications on news.